One notable example is the clinical trial agent APTO-253, which effectively inhibits c-MYC expression in various cancer cell lines, including those from colon cancer, leukemia, non-small-cell lung cancer, renal cancer, and prostate cancer [49,93]. The gene discussed is MYC; the disease is cancer.